

Biota Holdings Limited

ACN 006 479 081

10/585 Blackburn Road
Notting Hill VIC 3168
Australia**T** +61 3 9915 3700**F** +61 3 9915 3702**E** info@biota.com.au**W** www.biota.com.au

For Immediate Release

Melbourne, Australia — 4 February 2011

Relenza Royalty for December 2010 quarter

Biota Holdings Limited (ASX:BTA) advises that it has received written notification from GlaxoSmithKline that Relenza sales were \$17.9 million and indicative royalties were \$1.2 million, for the three months ended 31 December 2010. The figures were calculated on an Australian dollar exchange rate of 1.5186 to the UK pound, although the actual payment will be calculated on exchange rates at 30 April 2011.

Biota will report first half indicative Relenza royalty income of \$3.3 million when it releases its Interim Report on 16 February 2011.

About Biota

Biota is a leading anti-infective drug development company based in Melbourne Australia, with key expertise in respiratory diseases, particularly influenza. Biota developed the first-in-class neuraminidase inhibitor, zanamivir, subsequently marketed by GlaxoSmithKline as Relenza. Biota research breakthroughs include a series of candidate drugs aimed at treatment of respiratory syncytial virus (RSV) disease and Hepatitis C (HCV) virus infections. Biota has clinical trials underway with its lead compound for human rhinovirus (HRV) infection in patients with compromised respiration or immune systems.

In addition, Biota and Daiichi Sankyo co-own a range of second generation influenza anti-virals, of which the lead product Inavir[®], is approved for marketing in Japan.

Relenza[™] is a registered trademark of the GlaxoSmithKline group of companies.

Inavir[®] is registered to Daiichi Sankyo.

Investor / Analyst Enquiries**Biota Holdings Limited**

Peter Cook

T: +61 3 9915 3720

Damian Lismore

T: +61 3 9915 3721

Media Enquiries

Tim Duncan, Hinton & Associates

T: +61 3 9600 1979

US Enquiries

Hershel Berry, Blueprint Life Science Group

M: +1 415 505 3749